logo
Plus   Neg
Share
Email

I-Mab Prices IPO At $14.00/ADS, Within Estimated $12 To $15/ADS Range

Shanghai, China-based I-Mab said that it has priced its initial public offering of 7.41 million American Depositary Shares at $14.00 per ADS, within its previously estimated range of $12.00 to $15.00 per ADS.

The ADSs will begin trading on January 17, 2020 on the Nasdaq Global Market under the symbol "IMAB".

The company has granted the underwriters an option to purchase up to an additional 1.11 million ADSs within 30 days from the date of the final prospectus at $14.00 per ADS.

The company expects that the total gross proceeds from the offering to be about $103.70 million, assuming the underwriters do not exercise their option to purchase additional ADSs, or about $119.26 million, if the underwriters choose to exercise their option to purchase additional ADSs in full.

I-Mab is a clinical stage biopharmaceutical company developing novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Novacyt S.A. said it is seeing unprecedented demand for the novel coronavirus or COVID-19 diagnostic test kit developed by Primerdesign, the company's molecular diagnostics division based in the UK. As of March 27, Primerdesign has sold and received orders for more than 17.8 million pounds of its CE-Mark COVID-19 tests. Novacyt is currently selling its COVID-19 test to more than 80 countries. The U.S. Food and Drug Administration has issued an Emergency Use Authorization to allow anti-malaria drugs hydroxychloroquine sulfate and chloroquine phosphate donated to the Strategic National Stockpile as possible treatments for coronavirus (COVID-19) patients. This is the first EUA for a drug related to the COVID-19 response. Gilead Sciences Inc. said it is transitioning to "expanded access programs" from "compassionate use" programs for its experimental anti-coronavirus drug, remdesivir. The company noted that the expanded access will allow hospitals or physicians to apply for emergency use of remdesivir for multiple severely ill patients at one time, as they struggle to deal with the COVID-19 or coronavirus pandemic.
RELATED NEWS
Follow RTT
>